Units of CVS Health Corp., Cigna Group and UnitedHealth Group Inc. charged significantly more than the national average acquisition cost for dozens of specialty generic drugs, bringing in more than $7.3 billion in excess revenue over six years, the Federal Trade Commission said in a report on the drug middlemen.
The practice inflated costs for consumers and insurers on key treatments for cancer, multiple sclerosis, HIV, organ transplants and other conditions and procedures, the FTC said. The report demonstrates how pharmacy benefit managers influence every aspect of the pharmaceutical supply ch